Abstract:Bromodomain-containing protein 4 (BRD4) is critical in cell cycle regulation and has emerged as a potential target for treatment of various cancers. BRD4 contains two bromodomains, namely BDl and BD2. Research suggests that selectively inhibiting BDl or BD2 may provide more effective treatment options. Therefore, understanding the selective mechanism of inhibitor binding to BDl and BD2 is essential for development of high selective inhibitors to BDl and BD2. Multiple replica molecular dynamics (MRMD) simulations are utilized to investigate the binding selectivity of inhibitors SG3-179, GSK778, and GSK620 for BDl and BD2. The results show that BDl has stronger structural flexibility than BD2, moreover BDl and BD2 exhibit different internal dynamics. The analyses of free energy landscapes reveal significant differences in the conformational distribution of BDl and BD2. Binding free energy predictions suggest that entropy changes, electrostatic interactions, and van der Waals interactions are key factors in the selective binding of BDl and BD2 by SG3-179, GSK778, and GSK620. The calculations of the energy contributions of individual residues demonstrate that residues (W81, W374), (P82, P375), (Q85, K378), (V87, V380), (192, 1385), (N93, G386), (194, 1387), (C136, C429), (N140, N433), (K141, P434), (D144, H437) and (1146, V439) corresponding to (BDl, BD2) generate significant energy difference in binding of SG3-179, GSK778, and GSK620 to BDl and BD2, and they can serve as effective targets for development of high selective inhibitors against BDl or BD2. The related information may provide significant theoretical guidance for improving the selectivity of inhibitors for BDl and BD2.

A Theoretical Insight into Selectivity of Inhibitors Toward Two Domains of Bromodomain-Containing Protein 4 Using Molecular Dynamics Simulations

Selective Mechanism of Inhibitors to Two Bromodomains of BRD4 Revealed by Multiple Replica Molecular Dynamics Simulations and Free Energy Analyses

A Computational Insight into Binding Modes of Inhibitors XD29, XD35, and XD28 to Bromodomain-Containing Protein 4 Based on Molecular Dynamics Simulations.

Insight into Selective Mechanism of Class of I-BRD9 Inhibitors Toward BRD9 Based on Molecular Dynamics Simulations

Deciphering the mechanisms of selective inhibition for the tandem BD1/BD2 in the BET-bromodomain family.

Theoretical Exploration of the Binding Selectivity of Inhibitors to BRD7 and BRD9 with Multiple Short Molecular Dynamics Simulations

Binding Kinetics Versus Affinities in BRD4 Inhibition

Selectivity Mechanism of Pyrrolopyridone Analogues Targeting Bromodomain 2 of Bromodomain-Containing Protein 4 from Molecular Dynamics Simulations

Binding Mechanism of Inhibitors to BRD4 and BRD9 Decoded by Multiple Independent Molecular Dynamics Simulations and Deep Learning

Molecular mechanism of inhibitor bindings to bromodomain-containing protein 9 explored based on molecular dynamics simulations and calculations of binding free energies

Theoretical Research in Structure Characteristics of Different Inhibitors and Differences of Binding Modes with CBP Bromodomain

Classical Molecular Dynamics and Metadynamics Simulations Decipher the Mechanism of CBP30 Selectively Inhibiting CBP/p300 Bromodomains

Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations

Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation.

Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site

Identification of novel natural product inhibitors of BRD4 using high throughput virtual screening and MD simulation

Unveiling Allosteric Regulation and Binding Mechanism of BRD9 through Molecular Dynamics Simulations and Markov Modeling

Design, Synthesis and Biological Evaluation of Dihydroquinoxalinone Derivatives As BRD4 Inhibitors.

Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors

3D‐QSAR, Molecular Docking and Molecular Dynamics Analysis of 1,2,3,4‐tetrahydroquinoxalines As BRD4/BD2 Inhibitors

Study on Selectivity of Inhibitor BD2 for PKA over PKC beta II